 ns from the 
guidelines have been decided and no derogations from the procedure for implementation of the guidelines have been made. The auditor’s report regarding the company’s compliance with the guidelines is available on https://www.bioinvent.com/investors/corporate -governance/general- meetings/
. No remuneration has 
been reclaimed. In addition to remuneration covered by the remuneration guidelines, the annual general meetings of the company have resolved to implement long -term share -related incentive plans. 
 Table 1 – Total CEO remuneration in 2024 (KSEK)* 
 
 1 2 3 4 5 6 
 Fixed remuneration Variable remuneration 
Name of director 
(position) Base salary Other benefits* * One-year 
variable Multi -year 
variable ** * Extraordinary 
items Pension expense Total 
remuneration Proportion of fixed 
and variable 
remuneration **** 
Martin Welschof (CEO) 2,964 34 1,068 - - 890 4,956 78/22 
 
* Except for Multi -year variable remuneration, the table reports remuneration earned in 20 eration earned in 2024. Multi -year variable remuneration is reported if vested in 2024, as set out under Application of performance criteria 
below. 
** Travel and housing expenses in connection with travel to the office in Lund, Sweden. 
*** A share -based remuneration has been vested in 2024 , which is reported under Share -based remuneration below. 
**** Pension expense (column 4), which in its entirety relates to Base salary and is premium defined, has been counted entirely as fixed remuneration.

Share -based remuneration 
 
Outstanding share -related and share price -related incentive plans 
 
Option Program 2019/2025 
The 2019 a nnual general meeting resolved to adopt a long -term incentive program in the form of 
an employee stock option program comprising the management group. The option program 
comprise d a maximum of 3,971,000 employee stock options and the participants have vested 
options free of charge based on performance and continued employment. Granting of the optio ranting of the options 
took place during the second quarter of 2019. The CEO has vested 1/4 of the options during each of 
the financial years 20 19, 2020, 2021 and 2022 (other members of the management group have 
vested 1/3 of the options during each of the financial years 20 20, 202 1 and 202 2). 
 Option Program 2022/2024 The 2022 annual general meeting resolved to adopt a long -term incentive program in the form of 
an employee stock option program comprising all employees and other key persons in the 
company. The option program comprise a maximum of 820,000 employee stock options and 
granting of the options took place during the second quarter of 2022. The participants are vesting options free of charge , with 1/3 of the options during each of the financial years 2022, 2023 and 
2024, based on performance and continued employment. 
 
Option Program 20 23/2025 
The 20 23 annual general meeting resolved to adopt a long -term incentive program in the form of 
an employee stock op an employee stock option program comprising all employees and other key persons in the 
company. The option program comprise a maximum of 817,500 employee stock options and 
granting of the options took place during the second quarter of 2023. the participants are vesting options free of charge, with 1/3 of the options during each of the financial years 20 23, 20 24 and 
2025, based on performance and continued employment. 
 Option Program 20 24/2026 
The 2024 annual general meeting resolved to adopt a long -term incentive program in the form of 
an employee stock option program comprising all employees and other key persons in the company. The option program comprise a maximum of 890,000 employee stock options and granting of the options took place during the second quarter of 2024. the participants are vesting options free of charge, with 1/3 of the options during each of the financial years 2024, 2025 and 2026, based on performance and continued employment. 
 Further information is  ther information is available in note 4 on page 62-63 in the annual report 20 24. 
 
 
Application of performance criteria 
The performance criteria for the CEO's variable remuneration in the financial year 2 024 have mainly 
been linked to technical and commercial milestones within proprietary drug projects . The criteria 
have been chosen to contribute to the company's long -term strategy and to encourage acting that 
is in the company's long-term interest. No performance criteria have been linked to financial 
objectives . 
 
The performance criteria for 2 024 have been linked to achieved milestones in clinical operations, 
financing of operations, achieved milestones in preclinical operations, partnering and milestones in manufacturing operations. The measured outcome of the performance criteria achieved has been 
80% and based on this outcome, annual variable remuneration to the CEO has been paid (see Table 
1 above).

The Company granted a retention bonus to the CEO for the perio